Young Breast Cancer Survivors Without a Germline Pathogenic Variant Have a Low Risk of Developing a Second Primary Breast Cancer In the First 10 Years After Diagnosis
Findings from the Young Women’s Breast Cancer Study
Digital Health as Cancer Care Facilitator: the Power of a Standardised European Health Record 2024
23 Apr 2024
Chairs: Anna Pellat, Carola Schulz
Speakers: Maria Alice Borinelli-Franzoi, Daniëlle Seinstra, Henrique Martins
Programme
The MAP 2024 programme is now online!
Medical Oncologists Incredulous at the Commission’s Latest Backtracking on the Evaluation of the EU Tobacco Products Directive
Following the Ombudsman’s recent findings of maladministration regarding the Commission’s interactions with tobacco lobbyists and its subsequent decision not to bring forward the proposed Council recommendation on smoke-free environments, it is beyond belief that the Commission now appears to have removed plans to publish an evaluation – originally meant to come in 2022 - of the Tobacco Products Directive from its implementation
Patient Guide in Stomach Cancer Now Available in Hungarian
ESMO would like to thank the Gyógyulj Velünk Egyesület (GYVE) for providing translation in the Hungarian language
Efficacy and Safety of FOLFIRI With Durvalumab With or Without Tremelimumab as the Second-Line Treatment in Patients With Advanced Gastric/GEJ Adenocarcinoma
Findings from the PRODIGE 59-FFCD 1707-DURIGAST study
ESMO Advanced Course on Perioperative Strategies in Localized Malignancies: State of the Art and Future Directions in Lung Cancer 2024: Hong Kong SAR
Slides and Webcasts from all ESMO Advanced Courses are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. ESMO thanks the authors for their generosity.